Zhuoyuan Lin

Guangzhou, 510200, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

A novel biomarker SNHG11 promotes tumor progression and oxidative phosphorylation in clear cell renal cell carcinoma.

A novel biomarker SNHG11 promotes tumor progression and oxidative phosphorylation in clear cell renal cell carcinoma.

Journal: Acta biochimica et biophysica Sinica

Published: August 04, 2026

WTAP-mediated m6A modification of ARG2 mRNA Inhibits Its expression and drives prostate cancer malignant progression.

WTAP-mediated m6A modification of ARG2 mRNA Inhibits Its expression and drives prostate cancer malignant progression.

Journal: Mutation research

Published: March 28, 2025

Unveiling SMAD family member 6 as a novel biomarker for prognosis and immunotherapy response in testicular germ cell tumors.

Unveiling SMAD family member 6 as a novel biomarker for prognosis and immunotherapy response in testicular germ cell tumors.

Journal: Andrology

Published: November 14, 2024

GG-NER's role in androgen receptor signaling inhibitor response for advanced prostate cancer.

GG-NER's role in androgen receptor signaling inhibitor response for advanced prostate cancer.

Journal: Cell communication and signaling : CCS

Published: September 05, 2024

Aberrant Super-Enhancer Landscape in Enzalutamide-Resistant Prostate Cancer Cells.

Aberrant Super-Enhancer Landscape in Enzalutamide-Resistant Prostate Cancer Cells.

Journal: Genetic testing and molecular biomarkers

Published: May 09, 2024

Arginase 2 is a Diagnostic and Prognostic Marker for Prostate Cancer and Is Associated with Metabolism.

Arginase 2 is a Diagnostic and Prognostic Marker for Prostate Cancer and Is Associated with Metabolism.

Journal: Alternative therapies in health and medicine

Published: April 06, 2024

Different therapeutic regimens in the treatment of metastatic prostate cancer.

Different therapeutic regimens in the treatment of metastatic prostate cancer.

Journal: International journal of surgery (London, England)

Published: August 08, 2023

N6-methyladenosine modified lncRNAs signature for stratification of biochemical recurrence in prostate cancer.

N6-methyladenosine modified lncRNAs signature for stratification of biochemical recurrence in prostate cancer.

Journal: Human genetics

Published: May 26, 2023

A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer.

A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer.

Journal: Translational oncology

Published: January 25, 2023

Palmitoyl acyltransferase ZDHHC7 inhibits androgen receptor and suppresses prostate cancer.

Palmitoyl acyltransferase ZDHHC7 inhibits androgen receptor and suppresses prostate cancer.

Journal: Oncogene

Published: January 16, 2023

Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth.

Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth.

Journal: The Journal of clinical investigation

Published: October 13, 2022

Perillaldehyde inhibits bone metastasis and receptor activator of nuclear factor-κB ligand (RANKL) signaling-induced osteoclastogenesis in prostate cancer cell lines.

Perillaldehyde inhibits bone metastasis and receptor activator of nuclear factor-κB ligand (RANKL) signaling-induced osteoclastogenesis in prostate cancer cell lines.

Journal: Bioengineered

Published: November 05, 2021

Showing 1-12 of 16

Last Updated: 09/26/2026